biostudies-literatureORIGIN Trial InvestigatorsNational Institute for Health Research (NIHR)2915-22https://www.ebi.ac.uk/biostudies/studies/S-EPMC3781572biostudies-literatureUnknown36(10)<h4>Objective</h4>To assess the success and baseline predictors of maintaining glycemic control for up to 5 years of therapy using basal insulin glargine or standard glycemic care in people with dysglycemia treated with zero or one oral glucose-lowering agents.<h4>Research design and methods</h4>Data from 12,537 participants in the Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial were examined by baseline glycemic status (with or without type 2 diabetes) and by therapeutic approach (titrated insulin glargine or standard therapy) using an intention-to-treat analysis. Median values for fasting plasma glucose (FPG) and A1C and percentages with A1C<6.5% (48 mmol/mol) during randomized treatment were calculated. Factors independently associated with maintaining updated mean ADiabetes careCharacteristics associated with maintenance of mean A1C<6.5% in people with dysglycemia in the ORIGIN trial.PMC3781572RP-PG-0606-1272RP-DG-1210-10183Probstfield JLSpinas GARamachandran AGerstein HCHanefeld MJohnston PRosenstock JRyden LEDyal LRiddle MCORIGIN Trial InvestigatorsfalseCharacteristics associated with maintenance of mean A1C<6.5% in people with dysglycemia in the ORIGIN trial.<h4>Objective</h4>To assess the success and baseline predictors of maintaining glycemic control for up to 5 years of therapy using basal insulin glargine or standard glycemic care in people with dysglycemia treated with zero or one oral glucose-lowering agents.<h4>Research design and methods</h4>Data from 12,537 participants in the Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial were examined by baseline glycemic status (with or without type 2 diabetes) and by therapeutic approach (titrated insulin glargine or standard therapy) using an intention-to-treat analysis. Median values for fasting plasma glucose (FPG) and A1C and percentages with A1C<6.5% (48 mmol/mol) during randomized treatment were calculated. Factors independently associated with maintaining updated mean A2013-01-01T00:00:00Z2013 Oct2025-04-04T20:52:45.3Z2019-03-27T00:13:32ZS-EPMC37815722365698010.2337/dc12-2238